A key area of resistance to open science concerned relationships with industry. These partnerships can bring researchers valuable professional opportunities and offer important avenues for translation and patient benefit. Some interviewees worried that mandated data sharing may deter industry from sponsoring clinical trials. Indeed, the MNI has said it will not impose a specific timeline for release of trial data by sponsors (Poupon et al., 2017). However, researchers note that all patient-participant data will be captured within the MNI Open Science Clinical Biological Imaging and Genetic (C-BIG) biobank: this means that when information on a therapeutic molecule is disclosed by collaborators, this information can be easily integrated with the corresponding patient data. Further, some interviewees said that making data and biosamples openly accessible might reduce the attractiveness of MNI researchers to potential collaborators, who may want to operate under a more closed model. However, the public launch of open science at the MNI seems to have stoked interest of companies in a range of sectors including pharmaceuticals, imaging, deep learning, big data and information technology (Poupon et al., 2017). The initiative has also impelled major gifts from private donors (Stilgoe, 2016).